The results are presented of a case-control study conducted in the north of Iran. The main aim was to study factors identified in a previous study as potentially causally related to cancer of the oesophagus. Other tumours (lung, stomach, breast, large bowel, larynx and pharynx) were included to distinguish findings specific for oesophageal cancer from general characteristics of cancer patients, due for example to ascertainment bias, and to verify that expected associations, such as between lung cancer and cigarette smoking, would emerge under the prevailing field conditions. Two controls were chosen per case, matched for village of residence, age, sex and language group, Reinterviewing was performed to a limited extent to assess the accuracy of replies to questionnaires. The following were found not to be associated with oesophageal cancer: consumption of sheep's milk and yoghurt, sesame oil, chewing of nass, making of carpets, use of pregnancy diets, salting and sun-drying of meat and use of wild spinach. The use of opium, bread and tea could not be assessed in the retrospective framework. Strongly associated with risk of oesophageal cancer were low socio-economic status and low intake of fresh fruit and vegetables. The two factors each had an independent effect, and were more marked for oesophageal cancer than for the other tumours.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009866 | PMC |
http://dx.doi.org/10.1038/bjc.1979.54 | DOI Listing |
J Biochem Mol Toxicol
February 2025
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
This study aims to investigate the expression of GPER in EC, assess the impact of estrogen on the proliferation and migration of EC via GPER, and examine the potential role of GPER in mediating the NOTCH pathway to influence EC proliferation and migration. The expression of GPER and its correlation with clinicopathological features were investigated using clinical data. Cell proliferation was assessed through MTT and EdU assays, while cell migration ability was evaluated using wound healing and transwell assays.
View Article and Find Full Text PDFInt J Surg
January 2025
Department of Radiotherapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, China.
J Med Chem
January 2025
College of Chemistry, Zhengzhou University, Zhengzhou 450001, China.
The P2YR is activated by UDP and UDP glucose and is involved in many human inflammatory diseases. Based on the molecular docking analysis of currently reported P2YR antagonists and the crystallographic overlap study between PPTN and compound , a series of 3-substituted 5-amidobenzoate derivatives were designed, synthesized, and identified as promising P2YR antagonists. The optimal compound (methyl 3-(1-benzo[]imidazol-2-yl)-5-(2-(-tolyl) acetamido)benzoate, IC = 0.
View Article and Find Full Text PDFWorld J Gastroenterol
January 2025
Department of Thoracic Surgery, Northern Jiangsu People's Hospital, Yangzhou 225000, Jiangsu Province, China.
Background: The relationship between patient nutritional, immune, and inflammatory status is linked to tumor progression and prognosis. However, there are limited studies on the prognosis of esophageal squamous cell carcinoma (ESCC) after surgery based on the comprehensive indicators of these factors.
Aim: To develop and validate a novel nomogram based on a nutritional immune-inflammatory status (NIIS) score for predicting postoperative outcomes in ESCC.
Oncol Lett
March 2025
Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602-8566, Japan.
Nivolumab has been approved for unresectable recurrent advanced esophageal cancer. The present study aimed to provide real-world data on diverse patient profiles, including the elderly and those with poor performance status, while exploring therapeutic efficacy biomarkers. This retrospective study included 42 patients with esophageal cancer who received nivolumab after second- or later-line treatment at Kyoto Prefectural University of Medicine (Kyoto, Japan) from February 2020 to December 2021.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!